Stemline Therapeutics is planning to raise $50 mn in an IPO. The biotech company is planning to list on NASDAQ and trade under the symbol STML. The lead underwriters are Oppenheimer & Co and JMP Securities.

Click here for FREE email alerts from Inside IPO >>

Source: Renaissance Capital

Photo: bfishadow via Flickr